This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Benchmarks provide objective yardsticks to assess results, set expectations, and keep portfolios aligned with objectives.
20,321 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
The Education Department began sending notices on Wednesday, July 1, 2026, outlining deadlines and new options for fe...
Rising US energy costs are prompting a rethink on where to place AI data centers. Gulf-backed capacity powered by oil...
A high-profile casting announcement isn’t just entertainment news. It reveals how budgets, marketing, and risk affect...
Investors are spotting a familiar pattern that last showed up in 2020. This piece breaks down what the stock market j...
A digital dollar could change how money moves and how crypto stocks are valued. This guide breaks down what congress ...
As LNG exports push near capacity and data-center electricity demand climbs, three U.S. pipeline stocks paying wait o...
SK Hynix is lining up a U.S. listing on Nasdaq, aiming to raise about $28 billion as memory chips ride AI demand and ...
Rivian remains valued far below Ford despite big hype around electric-vehicle startups. With Rivian’s deliveries risi...
When celebrities face legal battles, the financial ripple effects reach far beyond courtroom walls. This article tran...
A fresh crypto phenomenon, the Robinhood Chain, has burst onto the scene, reshaping liquidity and retail participatio...
Eli Lilly sits at the center of the healthcare toolkit for many investors. This article breaks down the case for and ...